Bench-to-bedside: NIMH Research Leading to Brexanolone, First-Ever Drug Specifically for Postpartum Depression NIMH experts are available to provide information on postpartum depression and the importance of, and the science underlying, brexanolone.  Basic research findings from NIMH led a biopharmaceutical company to develop brexanolone, which is now approved by the FDA to treat postpartum depression by restoring levels of a particular metabolite that can drop following a pregnancy.  Learn More   Questions? Contact Us STAY CONNECTED: SUBSCRIBER SERVICES: Manage Preferences  |  Unsubscribe  |  Help  |  Subscribe to DSIR Portfolio Snapshots     This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Mental Health · 6001 Executive Boulevard · Bethesda, MD 20892-9663 · 1-866-615-6464